CTLA4 and metastatic melanoma: In monitoring MDSC in metastatic melanoma patients treated with the combination of tremelimumab/HDI, we first reported a significant regulatory impact on these cellular mediators of immunosuppression in a trial involving CTLA-4 blockade [29].